RBM15B/FOXM1/AURKA/TPX2 axis identified as key driver in endometrial cancer progression
RBM15B-mediated m6A modification of FOXM1 promotes endometrial cancer progression via the AURKA/TPX2 axis.
Phase III
endometrial cancer patients
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The identification of the RBM15B/FOXM1/AURKA/TPX2 axis as a key driver in endometrial cancer progression presents a significant opportunity for therapeutic intervention. This novel pathway could reshape treatment strategies and address unmet medical needs in oncology.
Recommended action
Humanexa recommends Investigate.
Analysis
Monitor developments in targeted therapies against the RBM15B/FOXM1/AURKA/TPX2 pathway and clinical trial outcomes.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.